Cyclin-dependent kinase 2 inhibitor SU9516 increases sensitivity of colorectal carcinoma cells Caco-2 but not HT29 to BH3 mimetic ABT-737

Gen Physiol Biophys. 2017 Dec;36(5):539-547. doi: 10.4149/gpb_2017030.


Colorectal carcinoma (CRC) that represents one of the major causes for cancer-related death in humans is often associated with over-expression of anti-apoptotic proteins of Bcl-2 family. The aim of presented study was to determine the effect of ABT-737 inhibitor of anti-apoptotic proteins Bcl-2, Bcl-XL and Bcl-w as well as cyclin-dependent kinase 2 (CDK2) inhibitor SU9516 alone and in combination with ABT-737 on survival of colorectal cell lines HT29 and Caco-2. We have shown that both Caco-2 and HT29 cells that are relatively resistant to ABT-737 are also partially sensitive to SU9516, which increased sensitivity of Caco-2 but not HT29 cells to ABT-737. Increased sensitivity of Caco-2 cells to ABT-737 after addition of SU9516 correlated well with SU9516-induced decrease of Mcl-1 expression while we have not observed downregulation of Mcl-1 after the treatment of HT29 cells with SU9516. Instead of this, we have shown that treatment of HT29 cells with SU9516 is associated with decreased expression of tumour suppressor protein p53. Our findings provide a rationale for clinical use of Bcl-2 family inhibitors in combination with CDK2 inhibitors for treatment of Mcl-1-dependent colorectal tumours associated with expression of Bcl-2, Bcl-XL and Bcl-w proteins. In addition, we have shown potential of CDK2 inhibitors for treatment of tumours expressing R273H mutant p53.

Publication types

  • Comparative Study

MeSH terms

  • Antineoplastic Combined Chemotherapy Protocols / administration & dosage*
  • Apoptosis / drug effects
  • BH3 Interacting Domain Death Agonist Protein / chemistry
  • Biphenyl Compounds / administration & dosage*
  • Biphenyl Compounds / chemistry
  • Caco-2 Cells
  • Cell Survival / drug effects
  • Colorectal Neoplasms / drug therapy*
  • Colorectal Neoplasms / enzymology*
  • Colorectal Neoplasms / pathology
  • Cyclin-Dependent Kinase 2 / antagonists & inhibitors*
  • Dose-Response Relationship, Drug
  • Drug Synergism
  • HT29 Cells
  • Humans
  • Imidazoles / administration & dosage*
  • Indoles / administration & dosage*
  • Nitrophenols / administration & dosage*
  • Nitrophenols / chemistry
  • Piperazines / administration & dosage
  • Piperazines / chemistry
  • Sulfonamides / administration & dosage*
  • Sulfonamides / chemistry
  • Treatment Outcome


  • ABT-737
  • BH3 Interacting Domain Death Agonist Protein
  • BID protein, human
  • Biphenyl Compounds
  • Imidazoles
  • Indoles
  • Nitrophenols
  • Piperazines
  • SU 9516
  • Sulfonamides
  • CDK2 protein, human
  • Cyclin-Dependent Kinase 2